Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

The S&amp;P 500 is consolidating under 2,954 - logical resistance - as market participants are in wait-and-see mode for incremental trade news ahead of the Trump/Xi G20 meeting later this week. While a breakout is certainly possible, we believe additional consolidation is the more likely scenario. In today's report we highlight a mix of positive and negative developments which lead us to this conclusion along with updates on other big picture trends. Also highlighted are attractive Groups and stocks within Materials, Health Care, and Utilities: Gold, Western Hemisphere, Cardiovascular Products, and Gas, Midwest.

The S&amp;P 500 is consolidating under 2,954 - logical resistance - as market participants are in wait-and-see mode for incremental trade news ahead of the Trump/Xi G20 meeting later this week. While a breakout is certainly possible, we believe additional consolidation is the more likely scenario. In today's report we highlight a mix of positive and negative developments which lead us to this conclusion along with updates on other big picture trends. Also highlighted are attractive Groups and stocks within Materials, Health Care, and Utilities: Gold, Western Hemisphere, Cardiovascular Products, and Gas, Midwest.

U.S. Dollar Breaking Down; Gold Breaking Out

Nasdaq-100 Stock Index / Technical Analysis

In this report we detail our U.S. investment thesis and provide a detailed technical appraisal of the broad market, as well as highlighting attractive investment opportunities within each of our 12 Sectors.

In this report we detail our U.S. investment thesis and provide a detailed technical appraisal of the broad market, as well as highlighting attractive investment opportunities within each of our 12 Sectors.

U.S. Equity Strategy: Defensive Areas Weakening; Broad Market Attempting to Bottom

<ul><li>U.S. equity markets remain resilient. Led by strength in technology and biotech, the Nasdaq hit a new all-time high yesterday. Small-cap indexes are also hitting all-time highs. Moreover, the S&amp;P 500 has moved to a new high relative to May prices, providing new evidence that the market is likely to continue its trend higher. Given these developments, our outlook continues to move toward the bullish camp. In today’s report we highlight attractive and actionable stocks within Energy (Refiners) and Health Care (Cardiovascular Products, and Surgical Devices &amp; Equipment).</li></ul>

U.S. equity markets remain resilient. Led by strength in technology and biotech, the Nasdaq hit a new all-time high yesterday. Small-cap indexes are also hitting all-time highs. Moreover, the S&amp;P 500 has moved to a new high relative to May prices, providing new evidence that the market is likely to continue its trend higher. Given these developments, our outlook continues to move toward the bullish camp. In today’s report we highlight attractive and actionable stocks within Energy (Refiners) and Health Care (Cardiovascular Products, and Surgical Devices &amp; Equipment).

U.S. Equity Strategy: Opportunities in Refiners & Med Device Makers

While defensive sectors continue to lag, one cyclical sector, Energy, has surged to the top of our relative strength rankings. Though we continue to expect further consolidation and volatility, current sector leadership and mostly positive breadth indicators point to a risk-on environment. In today’s report we highlight attractive and actionable groups within Energy and Health Care: EN-08 Oil and Gas E&amp;P, Domestic, Large-Cap, HC-11 Cardiovascular Products, and HC-13 Surgical Devices &amp; Equipment... see pages 10-21.

While defensive sectors continue to lag, one cyclical sector, Energy, has surged to the top of our relative strength rankings. Though we continue to expect further consolidation and volatility, current sector leadership and mostly positive breadth indicators point to a risk-on environment. In today’s report we highlight attractive and actionable groups within Energy and Health Care: EN-08 Oil and Gas E&amp;P, Domestic, Large-Cap, HC-11 Cardiovascular Products, and HC-13 Surgical Devices &amp; Equipment... see pages 10-21.

U.S. Equity Strategy: Opportunities in Energy & Health Care Stocks

Overwhelmingly, and to take a line from our U.S. Compass report, recent declines have corrected the excess. Where many charts appeared stretched and even parabolic in some cases, recent downward pressure on global equities has allowed many stocks to return to solid entry points near various areas of support. In today’s report we review every global sector, highlighting actionable stocks within each.

Overwhelmingly, and to take a line from our U.S. Compass report, recent declines have corrected the excess. Where many charts appeared stretched and even parabolic in some cases, recent downward pressure on global equities has allowed many stocks to return to solid entry points near various areas of support. In today’s report we review every global sector, highlighting actionable stocks within each.

United States

Edwards Lifesciences Corporation designs, develops, manufactures, and markets products and services to treat late-stage cardiovascular disease.  The Company's products include tissue replacement heart valves, heart valve repair products, hemodynamic monitoring devices, angioscopy equipment, oxygenators, and pharmaceuticals.  Edwards supplies its products to customers located worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Edwards Lifesciences (EW US)

U.S. Dollar Breaking Down; Gold Breaking Out

The S&P 500 is consolidating under 2,954 - logical resistance - as market participants are in wait-and-see mode for incremental trade news...

Vermilion Research

U.S. Equity Strategy: Defensive Areas Weakening; Broad Market Attempting to Bottom

In this report we detail our U.S. investment thesis and provide a detailed technical appraisal of the broad market, as well as highlighting...

Vermilion Research

U.S. Equity Strategy: Opportunities in Refiners & Med Device Makers

U.S. equity markets remain resilient. Led by strength in technology and biotech, the Nasdaq hit a new all-time high yesterday. Small-cap indexes...

Vermilion Research

U.S. Equity Strategy: Opportunities in Energy & Health Care Stocks

While defensive sectors continue to lag, one cyclical sector, Energy, has surged to the top of our relative strength rankings. Though we continue...

Vermilion Research

Global Equity Strategy

Overwhelmingly, and to take a line from our U.S. Compass report, recent declines have corrected the excess. Where many charts appeared stretched...

Vermilion Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)